Sponsor Overview
Explore verified public information about Mirati Therapeutics Inc.'s expanded access programs, compassionate use policies, and patient eligibility pathways. This report aggregates official statements, independent research, and regulatory data to help patients, providers, and sponsors collaborate efficiently.
Unique references curated across 1 content categories.
ClinicalTrials.gov data sources power this status.
Dataset refreshed continuously through Right2Hope ETL pipelines.
Expanded Access Intelligence
Past EAPs on ClinicalTrials.gov
Score contribution: 40 — 1 supporting sources.
Conditions: Advanced Cancer, Metastatic Cancer, Malignant Neoplasm
Reagan-Udall Foundation Insights
Single-Patient EA Policies/Criteria Single-Patient Expanded Access Policies and Criteria - A licensed physician who believes their patient may benefit from access to a Mirati investigational medicine outside of a clinical trial should contact Early Access Care, by email Mirati.ExpandedAccess@earlyaccesscare.com or by contacting the Mirati Expanded Access Call Center 1-475-522-2200. Available Therapies via Single-Patient EA Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation Conditions: Advanced solid tumors harboring a KRAS G12C mutation This is a multi-center, expanded access protocol to provide access to the investigational product, MRTX849, to adult patients with advanced solid tumors who have inadequate treatment options with available and approved therapies and who are otherwise ineligible for participating in clinical studies with MRTX829. Disease/Category-Specific EA Policies/Criteria https://www.earlyaccesscare.com/companies/mirati-therapeutics/adagrasib
Partner with Right2Hope
Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.